VACCINES AGAINST CHLAMYDIA TRACHOMATIS
Alexandria Linville (former)
We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for Chlamydia trachomatis vaccines. We identify antigens of interest that are important for Chlamydia trachomatis infection, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block Chlamydia trachomatis infection.
AL Collar, AC Linville, SB Core, CM Wheeler, WM Geisler, DS Peabody, B Chackerian, KM Frietze. 2020. Antibodies to variable domain 4 linear epitopes of the Chlamydia trachomatis major outer membrane protein are not associated with chlamydia resolution or reinfection in women. mSphere Sep 2020 5 (5) e00654-20
NIH/NIAID U19AI113187, EPIC-STI NIAID Cooperative Research Center
NIH/NIAID F30 Fellowship to Amanda Collar